科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06990 科伦博泰生物

休市中 06-18 16:08:08

415.800

+12.400

+3.07%

最高425.200	最低397.000	成交量122.55万
今开397.000	昨收403.400	日振幅6.99%
总市值968.81亿	流通市值710.95亿	总股本2.33亿
成交额5.07亿	换手率0.72%	流通股本1.71亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科伦博泰生物","latestPrice":415.8,"timestamp":1781770088007,"preClose":403.4,"halted":0,"volume":1225465,"delay":0,"changeRate":0.03073872087258313,"floatShares":170984257,"shares":233000000,"eps":-1.65683,"marketStatus":"休市中","change":12.4,"latestTime":"06-18 16:08:08","open":397,"high":425.2,"low":397,"amount":507498613,"amplitude":0.069906,"askPrice":415.8,"askSize":600,"bidPrice":414.4,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.843737,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782091800000},"marketStatusCode":7,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":403.4,"openAndCloseTimeList":[[1781746200000,1781755200000],[1781758800000,1781769600000]],"volumeRatio":1.220825861652471,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06990/tweets","defaultTab":"tweets","newsList":[{"id":"2644705357","title":"兴业证券：科伦博泰生物(06990)ASCO披露重磅肺癌数据 首予“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2644705357","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644705357?lang=zh_cn&edition=full","pubTime":"2026-06-18 15:51","pubTimestamp":1781769060,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，兴业证券发布研报称，科伦博泰生物在2026年ASCO大会上口头报告了sac-TMT联合K药一线治疗PD-L1TPS≥1% NSCLC的III期OptiTROP-Lung05研究结果。该行预计2026年至2028年收入分别为35.87亿元、43.55亿元、67.12亿元，归母净利润分别为0.75亿元、4.98亿元、14.34亿元，首次覆盖，给予“增持”评级。兴业证券主要观点如下：一线NSCLC大适应症临床3期数据意义重大该临床共有413例患者被随机(1:1)分配接受sac-TMT联合K药或K药单药治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601377","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643822932","title":"【券商聚焦】交银国际：医药行业上半年表现整体稳健 下半年内部分化或加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2643822932","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643822932?lang=zh_cn&edition=full","pubTime":"2026-06-15 10:21","pubTimestamp":1781490116,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，医药行业在1H26表现整体稳健、但内部分化也较为明显。短期关注出海交易、业绩表现和利好政策落地。推荐高景气度赛道中、投资性价比较高的头部玩家，包括药明合联、凯莱英和康龙化成。2026年港股龙头收入和净利润增速有望稳定在双位数。板块复苏积极信号已经出现。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983754","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YR35.GBP","09926","06821","01093","LU0502904849.HKD","01530","06990","01952","LU3063872942.SGD","LU0819121731.USD","LU2097828631.EUR","LU0051755006.USD","LU0348827113.USD","01951","02273","IE00B0JY6N72.USD","LU1226287875.USD","02269","LU1688375341.USD","03692","09996","00013","03329","01177","01801","02162","LU2399975544.HKD","02596","01548","02268","02096","09966","LU0320764599.SGD","LU0181495838.USD","HK0000306685.HKD","06160","06078","LU1960683339.HKD","03759","LU0737861772.HKD","01276","LU1242518857.USD","06996","LU1880383366.USD","BK1191","HK0000320264.USD","BK1576","LU0456827905.SGD","SG9999002562.SGD","LU0140636845.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141452520","title":"异动解读｜科伦博泰生物盘中上涨3.03%，宜联生物和解款7.03亿元到账持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1141452520","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141452520?lang=zh_cn&edition=full","pubTime":"2026-06-15 09:54","pubTimestamp":1781488488,"startTime":"0","endTime":"0","summary":"6月15日，科伦博泰生物盘中上涨3.03%，报420.2港元，成交额6105.08万港元。消息面上，公司于6月12日公告披露，已收到宜联生物医药根据和解协议支付的款项合计人民币7.03亿元，其中包含YL201对外授权应分享给公司的收入6.025亿元。根据双方和解协议，宜联生物需就其管线内包括YL201、YL212等6款ADC药物向科伦博泰分享对外授权收入及净利润，7.03亿元为\"首期兑现\"，后续管线授权里程碑达成及产品商业化仍有持续分成空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642257792","title":"港股异动 | 创新药概念多数走高 行业BD交易延续高景气 政策支持与商业化盈利兑现逻辑不变","url":"https://stock-news.laohu8.com/highlight/detail?id=2642257792","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642257792?lang=zh_cn&edition=full","pubTime":"2026-06-12 14:50","pubTimestamp":1781247029,"startTime":"0","endTime":"0","summary":"消息面上，今年一季度，中国创新药对外授权交易总额突破600亿美元，显示出海已从“偶发大单”升级为可持续的产业能力；另一方面，ASCO 2026中国研究入选数量和学术层级也在继续提升。近期多个创新药数据读出，重要BD陆续公告，事件性催化不断；中国创新药全球竞争力持续加强，政策支持与商业化盈利兑现的产业逻辑不变。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453619.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0196878994.USD","VXUS","BK4588","LU2543165471.USD","BK1161","BK1574","09969","LU1969619763.USD","LU0359201612.USD","LU2328871848.SGD","BK4585","01276","06978","LU0359202008.SGD","159992","BK1191","09995","06990","LU1023057109.AUD","LU0359201885.HKD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642254781","title":"医药板块集体回升 科伦博泰生物(06990)涨7.20%、荣昌生物(09995)涨6.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642254781","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642254781?lang=zh_cn&edition=full","pubTime":"2026-06-12 13:30","pubTimestamp":1781242214,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药板块集体回升，科伦博泰生物 涨7.20%，荣昌生物涨6.53%，康诺亚-B涨5.58%，复宏汉霖涨5.36%，康方生物涨5.07%，君实生物涨4.61%，药明合联涨4.06%，诺诚健华涨3.96%。英伟达同时为 Abridge 投资方，新模型基于英伟达开放模型套件 Nemotron 训练，Abridge 将采用去标识化临床数据进行定制优化，预计 2026 年晚些时候上线。东莞证券研报认为，受行业合规整顿以及消费疲软等因素影响，2025年医药生物行业整体归母净利润同比有所下滑。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983673","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320223.HKD","HK0000165453.HKD","LU1720050803.USD","02162","LU1794554557.SGD","BK1583","LU0348767384.USD","LU1961090484.USD","09926","BK1141","LU1969619763.USD","02696","LU2476274720.SGD","LU0348766576.USD","HK0000306701.USD","LU0348784397.USD","LU0348827113.USD","LU0417516571.SGD","BK1515","LU1064130708.USD","HK0000320264.USD","LU1064131003.USD","LU0540923850.HKD","LU2488822045.USD","LU0417516738.SGD","688331","HK0000306685.HKD","LU0348735423.USD","LU0348783233.USD","LU0417516902.SGD","LU0634319403.HKD","LU2148510915.USD","SG9999014674.SGD","LU2476274308.USD","09969","06990","BK0239","BK1161","BK1574","BK1587","IE00BPRC5H50.USD","LU0561508036.HKD","09995","LU2399975544.HKD","LU0348825331.USD","09939","02268","LU2328871848.SGD","01877","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642307622","title":"科伦博泰生物(06990)收到宜联生物医药根据已达成和解支付的相关款项","url":"https://stock-news.laohu8.com/highlight/detail?id=2642307622","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642307622?lang=zh_cn&edition=full","pubTime":"2026-06-12 08:02","pubTimestamp":1781222538,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物(06990)发布公告，有关本公司与苏州宜联生物医药有限公司(宜联生物医药)、薛彤彤博士、肖亮博士及蔡家强博士订立和解协议的相关事宜。根据已达成和解，本公司近日已收到宜联生物医药就YL201对外授权应分享给本公司的收入人民币6.025亿元。于2026年度及截至本公告日，本公司已收到宜联生物医药根据已达成和解支付的相关款项合计人民币7.027亿(包含前述人民币6.025亿元)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453467.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","161726","LU0196878994.USD","XBI","06990","399441","BK1161","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125223340","title":"科伦博泰生物获联拓药业6.025亿元，达成YL201项目对外授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1125223340","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125223340?lang=zh_cn&edition=full","pubTime":"2026-06-12 07:52","pubTimestamp":1781221941,"startTime":"0","endTime":"0","summary":"科伦博泰生物宣布，已与联拓药业就YL201项目达成对外授权协议，并据此获得总计6.025亿元人民币的款项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0196878994.USD","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126254438","title":"异动解读｜科伦博泰生物盘中下跌3.34%，生物科技板块集体走弱叠加董事长减持压力延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1126254438","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126254438?lang=zh_cn&edition=full","pubTime":"2026-06-11 10:02","pubTimestamp":1781143341,"startTime":"0","endTime":"0","summary":"6月11日，科伦博泰生物盘中下跌3.34%，报388.2港元，成交额5014.49万港元。板块层面，生物科技行业今日整体承压，百济神州跌2.94%、康方生物跌2.9%、三生制药跌2.55%、信达生物跌1.61%，创新药资产延续调整态势。个股层面，公司此前披露的业绩显示净亏损扩大至3.82亿元，授权及里程碑收入大幅缩减、研发费用高企为主要拖累，同时董事长连续减持信号持续压制短期市场信心。尽管多家券商近日维持\"买入\"评级且ASCO临床数据表现积极，但板块系统性走弱下个股仍难以独善其身。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642105174","title":"港股异动 | 超长效抗TSLP抗体II期临床完成首批给药 和铂医药-B(02142)、科伦博泰生物(06990)盘中均涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642105174","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642105174?lang=zh_cn&edition=full","pubTime":"2026-06-10 13:45","pubTimestamp":1781070342,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B、科伦博泰生物今日逆市走高，截至发稿，和铂医药涨3.46%，报9.86港元；科伦博泰生物涨3.82%，报402.2港元。消息面上，6月9日，科伦博泰宣布，其合作伙伴Windward Bio主导的一项II期临床研究已完成首批患者给药。据悉，SKB378/WIN378最初由科伦博泰与和铂医药共同开发，双方平分全球权益。若后续临床试验顺利推进，SKB378/WIN378有望成为首款获批上市的超长效抗TSLP抗体，用于哮喘和COPD治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452439.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990","BK1161","BK1583","LU0196878994.USD","BK4588","VXUS","02142","BK4585","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187758017","title":"异动解读｜科伦博泰生物盘中上涨3.25%，多家券商维持买入评级叠加ASCO数据持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1187758017","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187758017?lang=zh_cn&edition=full","pubTime":"2026-06-10 11:53","pubTimestamp":1781063609,"startTime":"0","endTime":"0","summary":"6月10日，科伦博泰生物盘中上涨3.25%，报400.0港元，成交额1.38亿港元。消息面上，野村近日维持公司\"买入\"评级并将目标价上调至544.42港元，中信建投亦维持\"买入\"评级，核心逻辑均指向公司芦康沙妥珠单抗III期OptiTROP-Lung05研究数据，联合用药组PFS风险比达0.35，系全球首个在PD-L1阳性非小细胞肺癌中显示PFS改善的ADC药物，成果已同步发表于《柳叶刀》。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166735631","title":"科伦博泰合作伙伴Windward Bio宣布首例患者入组SKB378/Win378针对COPD的二期Sirius研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1166735631","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166735631?lang=zh_cn&edition=full","pubTime":"2026-06-09 20:14","pubTimestamp":1781007283,"startTime":"0","endTime":"0","summary":"科伦博泰生物的合作方Windward Bio近日宣布，其用于治疗慢性阻塞性肺病的候选药物SKB378/Win378，已在名为“Sirius”的第二期临床研究中完成了对首批患者的给药。Sirius研究旨在评估SKB378/Win378在COPD患者中的安全性、耐受性及初步疗效，为后续的临床开发决策提供重要数据支持。此次研究的启动，是基于此前临床前及早期临床研究中观察到的积极信号。Windward Bio与科伦博泰生物的合作，整合了双方在药物研发领域的专业优势，共同推进该候选药物的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","BK1161","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642581466","title":"【券商聚焦】中信建投证券维持科伦博泰生物-B(6990.HK)“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2642581466","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642581466?lang=zh_cn&edition=full","pubTime":"2026-06-09 17:26","pubTimestamp":1780997189,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报指，科伦博泰生物-B 在2026年ASCO大会上公布核心产品Sac-TMT联合帕博利珠单抗一线治疗PD-L1阳性晚期非小细胞肺癌的III期OptiTROP-Lung05研究数据，结果显示联合组较帕博利珠单抗单药显著延长无进展生存期，总人群PFS风险比为0.35，12个月PFS率为62.4%对比29.0%；总生存期虽未成熟，但已观察到积极趋势。研报维持科伦博泰生物-B“买入”评级，未给出目标价。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983346","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177037255","title":"异动解读｜科伦博泰生物盘中下跌3.15%，董事长持续减持叠加业绩亏损扩大延续抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1177037255","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177037255?lang=zh_cn&edition=full","pubTime":"2026-06-08 10:24","pubTimestamp":1780885440,"startTime":"0","endTime":"0","summary":"6月8日，科伦博泰生物盘中下跌3.15%，报381.8港元，成交额5525.37万港元。此外，公司此前披露的业绩显示，尽管营收增长6.5%至20.58亿元，但净亏损扩大至3.82亿元，授权及里程碑收入大幅减少、研发费用高企为主要拖累。尽管公司已发布回购授权计划并在ASCO大会获得重磅临床数据支撑，但董事长连续减持信号仍对短期市场信心构成压制。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641177986","title":"东方证券：国产创新药开启NSCLC一线治疗范式革新","url":"https://stock-news.laohu8.com/highlight/detail?id=2641177986","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641177986?lang=zh_cn&edition=full","pubTime":"2026-06-08 09:55","pubTimestamp":1780883706,"startTime":"0","endTime":"0","summary":"东方证券主要观点如下：一代PD-1单药±化疗标准松动，NSCLC一线进入二代IO、ADC+IO双线迭代周期本届ASCO大会上，来自国产创新药的三项重磅临床数据表明，NSCLC一线金标准，即传统的PD-1±化疗的正迎来系统性替代。在免疫1.0时代，国产创新药大多跟随海外PD-1药物的研发，如今快速发展至引领免疫2.0时代，有望创造肺癌千亿市场治疗范式的全面革新。该研究是全球首个ADC+IO一线NSCLC取得III期阳性结果，有望改写PD-L1阳性NSCLC一线用药格局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451213.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2476274720.SGD","LU0348735423.USD","LU0455707207.USD","LU0561508036.HKD","LU1720050803.USD","BK0012","LU0417516571.SGD","LU0348766576.USD","LU2097828631.EUR","LU2476274308.USD","BK1574","LU2097828714.EUR","LU0348783233.USD","06990","IE00B543WZ88.USD","LU2488822045.USD","BK1161","LU0348825331.USD","LU2097828805.USD","LU0417516902.SGD","LU1961090484.USD","BK0183","LU0417516738.SGD","BK1564","09926","03958","LU0348784397.USD","IE00B5MMRT66.SGD","LU2328871848.SGD","LU2097828557.USD","BK1589","600958","LU0348827113.USD","LU0348767384.USD","159992","LU0634319403.HKD","01801","BK0028","LU0540923850.HKD","BK0276","IE00BPRC5H50.USD","LU1794554557.SGD","LU1969619763.USD","LU0502904849.HKD","HK0000165453.HKD","LU2097828474.EUR","BK1147","06978","LU0196878994.USD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152093512","title":"港股创新药概念股普涨，康诺亚-B、科伦博泰生物涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152093512","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152093512?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:54","pubTimestamp":1780624485,"startTime":"0","endTime":"0","summary":"6月5日，港股创新药概念股普涨，$康诺亚-B(02162)$、$科伦博泰生物(06990)$涨超5%，$恒瑞医药(01276)$、$信达生物(01801)$涨超4%，$药明康德(02359)$、$歌礼制药-B(01672)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"df6be86a5967f2b571d48b8ac559bb5d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","BK4585","BK1161","BK1587","VXUS","06978","BK1583","BK1574","06990","BK4588","LU0196878994.USD","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641196028","title":"港股异动 | 科伦博泰生物(06990)涨超7% OptiTROP-Lung05研究实现里程碑突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2641196028","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641196028?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:45","pubTimestamp":1780623930,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物涨超7%，截至发稿，涨6.87%，报417港元，成交额9442.01万港元。消息面上，据科伦博泰生物官微消息，在ASCO 2026年会上，公司芦康沙妥珠单抗联合帕博利珠单抗1L治疗晚期PD-L1阳性非小细胞肺癌的国内注册I川期临床OptiTROPLung05结果以口头汇报形式展示，该成果同时发表于《柳叶刀》。这是全球首个TROP2ADC联合免疫1L治疗NSCLC达到主要终点的I期研究。中金认为，该适应症在国内已经递交上市申请，未来有潜力重塑PD-L1阳性1L NSCLC治疗格局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1161","BK4585","06990","BK4588","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172136449","title":"异动解读｜科伦博泰生物盘中上涨3.54%，回购计划叠加ASCO临床数据持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1172136449","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172136449?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:35","pubTimestamp":1780623318,"startTime":"0","endTime":"0","summary":"6月5日，科伦博泰生物盘中上涨3.54%，报405.8港元，成交额2817.64万港元。消息面上，公司于6月4日发布公告，拟提请股东大会审议授权董事会回购不超过已发行H股总数10%的股份，释放积极信号。此外，公司核心产品芦康沙妥珠单抗III期研究成果近期于ASCO大会口头报告并同步发表于《柳叶刀》，数据显示在PD-L1阳性非小细胞肺癌中PFS风险比达0.35，系全球首个在该适应症中显示PFS改善的ADC药物。此前该股因业绩亏损扩大及董事长减持一度承压，回购方案叠加重磅临床数据有助修复市场情绪。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152331396","title":"异动解读｜科伦博泰生物开盘上涨3.08%，拟回购不超过10%已发行H股提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1152331396","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152331396?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:21","pubTimestamp":1780622505,"startTime":"0","endTime":"0","summary":"6月5日，科伦博泰生物开盘上涨3.08%，报402.2港元。消息面上，公司于6月4日发布公告，拟提请股东大会审议授权董事会回购不超过已发行H股总数10%的股份，回购计划释放积极信号。此外，公司核心产品芦康沙妥珠单抗III期研究成果近期于ASCO口头报告并同步发表于《柳叶刀》，双抗ADC SKB571新适应症II期临床也获NMPA批准，管线持续推进为股价提供支撑。此前该股因业绩亏损扩大及董事长减持一度承压，回购方案有助修复市场情绪。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105082931","title":"科伦博泰生物(06990)拟回购不超过已发行H股10%的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1105082931","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105082931?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:37","pubTimestamp":1780562266,"startTime":"0","endTime":"0","summary":"科伦博泰生物于2026年6月4日发布公告，计划在2026年6月29日举行年度股东大会，并拟提请股东审议授权公司董事会回购不超过未来股东大会通过决议日公司已发行H股总数10%的股份。公司近日亦披露，过去12个月间，科伦博泰生物H股股价最高曾于2025年10月触及每股港币581.00元，最低则于2025年5月为港币296.20元。科伦博泰生物将于2026年6月24日至29日暂时关闭股东登记，以确定可出席并表决本次年度股东大会的股东资格。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科伦博泰生物(06990)拟回购不超过已发行H股10%的股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176368841","title":"科伦博泰生物5月无新增发行及股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1176368841","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176368841?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:36","pubTimestamp":1780562199,"startTime":"0","endTime":"0","summary":"四川科伦博泰生物医药股份有限公司于2026年6月4日披露，截至2026年5月31日的股份变动月报表。报告显示，截至2026年5月末，科伦博泰生物H股已发行股份为170,984,257股，内资股为62,201,712股，二者均与上月结存数相同；本月未发生新增发行、购回或注销，也不存在新增库存股份。另据公告，科伦博泰生物于2025年12月通过股份激励计划，计划授予366名承授人合计435,064份限制性股票单位，未来通过发行新H股完成。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://kelun-biotech.com","stockEarnings":[{"period":"1week","weight":0.0543},{"period":"1month","weight":-0.0321},{"period":"3month","weight":-0.0043},{"period":"6month","weight":-0.0081},{"period":"1year","weight":0.2137},{"period":"ytd","weight":0.0602}],"compareEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0726},{"period":"3month","weight":-0.0535},{"period":"6month","weight":-0.0687},{"period":"1year","weight":0.009},{"period":"ytd","weight":-0.0666}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四川科伦博泰生物医药股份有限公司是一家主要从事新药业务的研发、生产和销售的中国公司。该公司主要从事肿瘤学、免疫学及其他治疗领域的创新药物的研发、制造及商业化。该公司的产品有抗体药物偶联物（ADC）SKB264和A166等。该公司产品主要用于乳腺癌、非小细胞肺癌、胃肠道癌等疾病的治疗。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.05939},{"month":2,"riseRate":0.666667,"avgChangeRate":0.239909},{"month":3,"riseRate":1,"avgChangeRate":0.292496},{"month":4,"riseRate":1,"avgChangeRate":0.083557},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.011152},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.037368},{"month":7,"riseRate":0.5,"avgChangeRate":0.112175},{"month":8,"riseRate":1,"avgChangeRate":0.047459},{"month":9,"riseRate":1,"avgChangeRate":0.084769},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.03489},{"month":11,"riseRate":1,"avgChangeRate":0.072292},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.053467}],"exchange":"SEHK","name":"科伦博泰生物","nameEN":"SKB BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦博泰生物(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦博泰生物,06990,科伦博泰生物股票,科伦博泰生物股票老虎,科伦博泰生物股票老虎国际,科伦博泰生物行情,科伦博泰生物股票行情,科伦博泰生物股价,科伦博泰生物股市,科伦博泰生物股票价格,科伦博泰生物股票交易,科伦博泰生物股票购买,科伦博泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦博泰生物(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}